Pulse Biosciences, Inc. (NASDAQ:PLSE) Files An 8-K Other EventsItem 8.01 Other Events
On April 18, 2017, the underwriter of the Company’s initial public offering, MDB Capital Group LLC, informed the Company that it had immediately and irrevocably waived the lock-up provisions for pre-IPO stockholders holding approximately 3.9 million shares of the Company’s Common Stock. These stockholders, which include certain of the Company’s directors and 5% holders would have been subject to the lock-up until May 17, 2017 under the terms of the existing lock-up agreements.
About Pulse Biosciences, Inc. (NASDAQ:PLSE)
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes. Pulse Biosciences, Inc. (NASDAQ:PLSE) Recent Trading Information
Pulse Biosciences, Inc. (NASDAQ:PLSE) closed its last trading session down -0.45 at 25.15 with 336,750 shares trading hands.